A Fast Track designation, seventeen months to anticipated approval, and more than forty interconnected commercial strategy decisions: a clinical-stage biotech’s first launch, with no room to decide anything twice.
The Fast Track letter changed the clock. Suddenly the company was seventeen months from anticipated approval, and every corporate function was staring at its own long list of launch decisions, with no launch organization, no planning process, and no view of what had to be decided by whom, and when. The danger was the classic one: missing the forest, the few critical strategic choices that disproportionately decide launch success, for the trees, the hundreds of activities everyone was busy executing. THRIVE was engaged by the CEO and the board to find the forest and cut the road through it.
Some of the most valuable output was never on the original list: entire workstreams critical to launch that no one had been planning, or budgeting, for. The decision system made the gaps visible in time to close them.
If your organization is launching a new therapy where failure is not an option, let’s talk.
Start a conversation